CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a biotechnology company that develops innovative therapies for serious diseases in neurology and oncology. These therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending and include prevalent and difficult-to-treat diseases with significant unmet medical needs. The company aims to build a differentiated portfolio of assets with best-in-class potential. On January 1, 2026, Rami Levin, MBA, was appointed President & Chief Executive Officer. Following this, an independent life science focused advisory firm conducted a comprehensive data-driven analysis of the company's pipeline, development priorities, and long-term positioning. While this Strategic Analysis was underway, the company rebuilt its executive leadership team, appointing a new Chief Business Officer, Chief Financial Officer, Chief Medical Officer, and Chief Technology Officer effective March 2, 2026. This team was assembled to execute the findings and recommendations of the Strategic Analysis and develop a new corporate strategy. On March 11, 2026, CNS Pharmaceuticals announced a new corporate growth strategy focused on building a high-value pipeline in neurology and oncology. This strategy resulted from the comprehensive, data-driven strategic review, which included clinical probability-of-success modeling, competitive landscape assessments, regulatory pathway analyses, and risk-adjusted return evaluations.